Anxo (6677) and Sunny Pharmtech (6676) have signed a cooperation agreement to jointly develop high-margin cardiovascular drugs aimed at challenging the patents of originator (Paragraph IV). 

Anxo will handle early-stage research and development, patent non-infringement studies, and technology transfer, while Sunny Pharmtech will oversee commercialization. 

They plan to share development costs and future profits. This partnership builds on prior successful collaborations, expanding their reach into global markets including Asia-Pacific, North America, and Europe.